menu
    • menu
    [{"orgOrder":0,"company":"Pharmascience Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Cholestyramine","moa":"Bile acids","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Pharmascience Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Pharmascience Inc. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pharmascience Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Pharmascience Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Teriflunomide","moa":"Dihydroorotate dehydrogenase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Pharmascience Inc.","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Pharmascience Inc. \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pharmascience Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Pharmascience Inc.","sponsor":"Royal DSM | MDEIE Ministry, Qu\u00e9bec Government | INRS-Institut Armand Frappier","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cytotoxic Drug","year":"2012","type":"Inapplicable","leadProduct":"Decitabine","moa":"DNA (cytosine-5)-methyltransferase 1 | DNA | DNA (cytosine-5)-methyltransferase 3A","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pharmascience Inc.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pharmascience Inc. \/ Royal DSM | MDEIE Ministry, Qu\u00e9bec Government | INRS-Institut Armand Frappier","highestDevelopmentStatusID":"7","companyTruncated":"Pharmascience Inc. \/ Royal DSM | MDEIE Ministry, Qu\u00e9bec Government | INRS-Institut Armand Frappier"},{"orgOrder":0,"company":"Pendopharm","sponsor":"KalVista Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Licensing Agreement","leadProduct":"Sebetralstat","moa":"KLKB1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Pendopharm","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pendopharm \/ Pendopharm Division of De Pharmascience Inc","highestDevelopmentStatusID":"15","companyTruncated":"Pendopharm \/ Pendopharm Division of De Pharmascience Inc"},{"orgOrder":0,"company":"Pharmascience Inc.","sponsor":"Pharmascience Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Colchicine","moa":"Tubulin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pharmascience Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pharmascience Inc. \/ Pharmascience Inc.","highestDevelopmentStatusID":"10","companyTruncated":"Pharmascience Inc. \/ Pharmascience Inc."},{"orgOrder":0,"company":"Pharmascience Inc.","sponsor":"Pharmascience Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Colchicine","moa":"Tubulin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pharmascience Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pharmascience Inc. \/ Pharmascience Inc.","highestDevelopmentStatusID":"10","companyTruncated":"Pharmascience Inc. \/ Pharmascience Inc."},{"orgOrder":0,"company":"Pharmascience Inc.","sponsor":"Pharmascience Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Colchicine","moa":"Tubulin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pharmascience Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pharmascience Inc. \/ Pharmascience Inc.","highestDevelopmentStatusID":"10","companyTruncated":"Pharmascience Inc. \/ Pharmascience Inc."},{"orgOrder":0,"company":"Pharmascience Inc.","sponsor":"Pharmascience Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Colchicine","moa":"Tubulin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Pharmascience Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pharmascience Inc. \/ Pharmascience Inc.","highestDevelopmentStatusID":"10","companyTruncated":"Pharmascience Inc. \/ Pharmascience Inc."},{"orgOrder":0,"company":"Pendopharm","sponsor":"Pendopharm","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Colchicine","moa":"Tubulin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Pendopharm","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Pendopharm \/ PENDOPHARM DIVISION OF DE PHARMASCIENCE INC","highestDevelopmentStatusID":"15","companyTruncated":"Pendopharm \/ PENDOPHARM DIVISION OF DE PHARMASCIENCE INC"},{"orgOrder":0,"company":"Pharmascience Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Colchicine","moa":"Tubulin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Pharmascience Inc.","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Pharmascience Inc. \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pharmascience Inc. \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Pharmascience Inc.

    Menu

    Pharmascience Inc.

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Pendopharm

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Pendopharm

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sebetralstat

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Recipient : KalVista Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            KalVista Enters into Agreement with Pendopharm to Commercialize Sebetralstat in Canada

                            Details : Pendopharm has the exclusive rights to manage the regulatory approval process and commercialization of KVD900 (sebetralstat), an investigational, oral on-demand treatment for hereditary angioedema.

                            Product Name : KVD900

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            June 26, 2025

                            Lead Product(s) : Sebetralstat

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Recipient : KalVista Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Pharmascience Inc.

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Pharmascience Inc.

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Teriflunomide

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pharmascience Canada is Thrilled to Launch (PR)pms-Teriflunomide

                            Details : Aubagio-Generic (teriflunomide) is an immunomodulatory agent with anti-inflammatory properties, inhibits dihydroorotate dehydrogenase. It is indicated for the treatment of patients with relapsing remitting multiple sclerosis.

                            Product Name : pms-Teriflunomide

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 27, 2022

                            Lead Product(s) : Teriflunomide

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Pharmascience Inc.

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Pharmascience Inc.

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Colchicine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pharmascience Introduces Myinfla(TM) (Colchicine 0.5 Mg Extended-Release Tablets), a New Repurposed Treatment ...

                            Details : Myinfla (colchicine 0.5 mg extended-release tablets) inhibits the Beta tubulin polymerisation, which is indicated for the reduction of atherothrombotic events in adult patients with existing coronary artery disease.

                            Product Name : Myinfla

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            September 22, 2021

                            Lead Product(s) : Colchicine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Pendopharm

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Pendopharm

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Colchicine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Recipient : Montreal Heart Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Health Canada Approval of Low-Dose Colchicine for Cardiovascular Disease Based on The COLCOT Study

                            Details : Health Canada has issued a Notice of Compliance for the prescription drug MYINFLA™ (colchicine 0.5 mg tablets) based on the results of the Montreal Heart Institute (MHI)’s COLCOT clinical trial.

                            Product Name : Myinfla

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            August 27, 2021

                            Lead Product(s) : Colchicine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Recipient : Montreal Heart Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Pharmascience Inc.

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Pharmascience Inc.

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Colchicine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Recipient : Montreal Heart Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Colchicine Reduces the Risk of COVID-19-related Complications

                            Details : Colchicine tablets inhibits the beta tubulin polymerisation, which is investigated for the treatment of COVID-19 infection in non-hospitalized patients.

                            Product Name : Myinfla

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            January 23, 2021

                            Lead Product(s) : Colchicine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Recipient : Montreal Heart Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Pharmascience Inc.

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Pharmascience Inc.

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Colchicine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Recipient : Montreal Heart Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Colchicine Shows Promise as a Treatment for at-home COVID-19 Patients

                            Details : Colchicine tablets inhibits the beta tubulin polymerisation, which is investigated for the treatment of COVID-19 infection in non-hospitalized patients.

                            Product Name : Myinfla

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            November 29, 2020

                            Lead Product(s) : Colchicine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Recipient : Montreal Heart Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Pharmascience Inc.

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Pharmascience Inc.

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Colchicine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Recipient : Montreal Heart Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pharmascience Reiterates Its Support to the Montreal Heart Institute's Colchicine Repurposing Research Studies...

                            Details : The first of these sub analyses simultaneously published in the European Heart Journal reveals that early initiation of low-dose colchicine within the first 3 days after MI significantly reduces the risk of ischemic CV events by 48% as vs placebo on top ...

                            Product Name : Myinfla

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            August 31, 2020

                            Lead Product(s) : Colchicine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Recipient : Montreal Heart Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Pharmascience Inc.

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Pharmascience Inc.

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Colchicine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Recipient : Montreal Heart Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Montreal Heart Institute Announces COLCORONA Trial in Patients with COVID-19 Passes Futility Test in Interim A...

                            Details : Colchicine tablets inhibits the beta tubulin polymerisation, which is investigated for the treatment of COVID-19 infection in non-hospitalized patients.

                            Product Name : Myinfla

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            January 30, 2020

                            Lead Product(s) : Colchicine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Recipient : Montreal Heart Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Pharmascience Inc.

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Pharmascience Inc.

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cholestyramine

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy, Safety and Tolerability of Enteric-Coated Cholestyramine Capsules for Adult Short Bowel Syndrome

                            Details : Cholestyramine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Short Bowel Syndrome.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 06, 2019

                            Lead Product(s) : Cholestyramine

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Pharmascience Inc.

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Pharmascience Inc.

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Decitabine

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Royal DSM | MDEIE Ministry, Québec Government | INRS-Institut Armand Frappier

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MTD Determination, Safety and Efficacy of the Decitabine-Genistein Drug Combination in Advanced Solid Tumors a...

                            Details : Decitabine is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            June 26, 2012

                            Lead Product(s) : Decitabine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Royal DSM | MDEIE Ministry, Québec Government | INRS-Institut Armand Frappier

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth